32 個單集

ESMO Open is the European Society for Medical Oncology’s online-only, peer-reviewed Open Access journal, dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research.

ESMO Open talk medicine

    • 醫學

ESMO Open is the European Society for Medical Oncology’s online-only, peer-reviewed Open Access journal, dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research.

    Highlights in Lung Cancer 2019

    Highlights in Lung Cancer 2019

    There has been a lot of exciting trials in lung cancer reported in 2019. In this podcast, Jonathan Lim (YOC member) speaks to Professor Sanjay Popat about how these studies are practice-changing in the context of the current treatment landscape, and highlights what is on the horizon for 2020 (including targeting KRAS).

    • 26 分鐘
    Current biomarkers in immunotherapy

    Current biomarkers in immunotherapy

    Immunotherapy approaches have revolutionized medical oncology in the last years. However, still only a fraction of patients is responding. Given the risk of side effects without efficacy, therefore, biomarkers providing reliable and reproducible prediction of response are urgently needed. In this podcast, next generation biomarkers including the challenge of branched genomic evolution of cancer are discussed by Professor Samra Turajlic, The Royal Marsden Hospital, London, UK.

    • 4 分鐘
    ESMO Presidential Symposium: Final overall survival analysis from the FLAURA trial

    ESMO Presidential Symposium: Final overall survival analysis from the FLAURA trial

    Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis.
    The phase III trial Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA) showed a significant increase in progression free survival. In the now available finale survival analysis also the overall survival showed a statistical significant increase.
    Expert: Suresh S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta, GA

    • 6 分鐘
    ESMO Presidential Symposium: Phase III PAOLA-1: Olaparib in newly diagnosed, advanced ovarian cancer

    ESMO Presidential Symposium: Phase III PAOLA-1: Olaparib in newly diagnosed, advanced ovarian cancer

    The present podcast gives a short summary of the PAOLA-1 trial investigating the addition of Olaparib to bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab.
    Expert: Isabelle L. Ray-Coquard
    Affiliation: Centre Leon Bèrard, Université Claude Bernard Lyon, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers de l'Ovaire (GINECO), Lyon, France

    • 5 分鐘
    Reimbursement Reality for Off-label use (OLU) of Drug Treatments in Cancer Care

    Reimbursement Reality for Off-label use (OLU) of Drug Treatments in Cancer Care

    In this podcast, Marina Parry, ESMO Open Digital Editor, speaks to Amanda Herbrand, Medical Oncologist Trainee working at University Hospital Basel, Switzerland, about her team’s work on off-label use (OLU) of Drug Treatments in Cancer Care, presented at ESMO Congress 2019 and a preprint of which is available on medRxiv: https://www.medrxiv.org/content/10.1101/19003152v1
    With new drug treatments for cancer patients constantly being investigated in clinical trials, ensuring access to the ones which prove to be effective in improving patient care is critical. These drugs are initially assessed by medical authorities for their efficacy and cost effectiveness, which means it can take time before they are approved. However, physicians will sometimes wish to use therapies which have been shown to be effective in clinical trials but without specific approval in the disease setting they are treating. This leads to off-label use (OLU) of cancer therapies, which, depending on the healthcare system, is not covered by patients’ health insurance. Dr Herbrand and her team set out to understand what the reasons were behind insurers’ acceptance or denial of payment for OLU of drug treatments for cancer patients within the Swiss healthcare system. They investigated the relationship between reimbursement decisions and the underlying clinical evidence by extracting patient characteristics and treatment and reimbursement details of cancer drugs from over 3,000 patients in 3 Swiss hospitals, and created an evidence overview of the requested OLU indications. Their study provides a systematic assessment of OLU and its reimbursement reality in Switzerland. This may provide a better understanding of the access to cancer care that is regulated by health insurers and identify factors that determine the level of evidence-based cancer care in a highly diverse Western healthcare system. Further work will be undertaken as a follow up to this study.
    These data are preliminary and further work will be undertaken as a follow up to this study.

    • 18 分鐘
    The ESMO-Magnitude of Clinical Benefit Scale Group

    The ESMO-Magnitude of Clinical Benefit Scale Group

    Despite all the efforts done so far, access to essential drugs in Oncology is still asymmetric. In this podcast, Teresa Amaral, member of the ESMO YOC, interviews Professor Martine Piccart (Scientific Director of the Institut Jules Bordet, Universite Libre de Bruxelles, Belgium) that shares valuable insights on the work that has been done on this field by the ESMO Magnitude of Clinical Benefit Scale (ESMO – MCBS) group.
    You can find more information about the ESMO-MCBS group in the following publications:
    https://doi.org/10.1093/annonc/mdv249
    http://dx.doi.org/10.1136/esmoopen-2017-000216
    More information on the ESMO Magnitude of Clinical Benefit Scale: Scale Evaluation Forms v1.0 & v1.1 can be found here:
    https://www.esmo.org/Guidelines/ESMO-MCBS/Scale-Evaluation-Forms-v1.0-v1.1
    You can read the complete Abstract relating to this podcast on the ESMO Open website: https://esmoopen.bmj.com/content/4/5/e000594.

    • 16 分鐘

熱門醫學 Podcast

聽眾訂閱的還有